Zimmer Biomet Holdings Inc. (NYSE:ZBH) hit a new 52-week high during trading on Thursday . The stock traded as high as $126.65 and last traded at $126.25, with a volume of 301,606 shares trading hands. The stock had previously closed at $125.57.

Several equities research analysts have recently commented on the company. Argus raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $140.00 target price for the company in a report on Wednesday, May 25th. Zacks Investment Research raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $135.00 target price for the company in a report on Monday, July 4th. Canaccord Genuity reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Wednesday, June 8th. Morgan Stanley reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Wednesday, June 8th. Finally, Guggenheim assumed coverage on Zimmer Biomet Holdings in a report on Wednesday, June 8th. They set a “neutral” rating for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $124.50.

The stock has a market cap of $25.17 billion and a P/E ratio of 311.13. The firm has a 50 day moving average of $120.31 and a 200 day moving average of $109.01.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, April 28th. The company reported $2.00 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.07. The firm earned $1.90 billion during the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter last year, the firm earned $1.54 earnings per share. The business’s revenue for the quarter was up 67.8% on a year-over-year basis. On average, equities research analysts expect that Zimmer Biomet Holdings Inc. will post $7.96 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Stockholders of record on Friday, June 24th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, June 22nd. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%.

In other news, CFO Daniel P. Florin sold 15,000 shares of the business’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $124.98, for a total value of $1,874,700.00. Following the sale, the chief financial officer now directly owns 16,983 shares in the company, valued at $2,122,535.34. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Tony W. Collins sold 3,611 shares of the business’s stock in a transaction dated Tuesday, June 14th. The shares were sold at an average price of $116.43, for a total value of $420,428.73. Following the completion of the sale, the chief accounting officer now owns 3,245 shares in the company, valued at $377,815.35. The disclosure for this sale can be found here.

A number of hedge funds recently added to or reduced their stakes in the company. Whittier Trust Co. bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at about $1,022,000. Employees Retirement System of Texas bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at about $1,026,000. Liberty Mutual Group Asset Management Inc. bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at about $1,029,000. Amica Mutual Insurance Co. bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at about $1,064,000. Finally, Commerzbank Aktiengesellschaft FI bought a new stake in Zimmer Biomet Holdings during the fourth quarter valued at about $1,104,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.